Differential modulation of apoptosis sensitivity in CD95 type I and type II cells

被引:504
|
作者
Scaffidi, C
Schmitz, I
Zha, JP
Korsmeyer, SJ
Krammer, PH
Peter, ME
机构
[1] German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1074/jbc.274.32.22532
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have recently identified two different pathways of CD95-mediated apoptosis (Scaffidi, C., Fulda, S., Srinivasan, A., Feng, L., Friesen, C., Tomaselli, K, J,, Debatin, K.-M,, Krammer, P. H., and Peter, M.E. (1998) EMBO J. 17, 1675-1687), CD95-mediated apoptosis in type I cells is initiated by large amounts of active caspase-8 formed at the death-inducing signaling complex (DISC) followed by direct cleavage of caspase-3, In contrast, in type II cells very little DISC and small amounts of active caspase-8 sufficient to induce the apoptogenic activity of mitochondria are formed causing a profound activation of both caspase-8 and caspase-3, Only in type II cells can apoptosis be blocked by overexpressed Bcl-2 or Bcl-x(L). We now show that a number of apoptosis-inhibiting or -inducing stimuli only affect apoptosis in type II cells, indicating that they act on the mitochondrial branch of the CD95 pathway. These stimuli include the activation of protein kinase C, which inhibits CD95-mediated apoptosis resulting in a delayed cleavage of BID, and the induction of apoptosis by the ceramide analog C-2-ceramide, In addition, we have identified the CD95 high expressing cell line Boe(R) as a CD95 apoptosis-resistant type II cell that can be sensitized by treatment with cycloheximide without affecting formation of the DISC, This also places the effects of cycloheximide in the mitochondrial branch of the type II CD95 pathway. In contrast, c-FLIP was found to block CD95-mediated apoptosis in both type I and type II cells, because it acts directly at the DISC of both types of cells.
引用
收藏
页码:22532 / 22538
页数:7
相关论文
共 50 条
  • [21] Activation of Fas (CD 95) induces lung injury and apoptosis of type I and II pneumocytes in mice
    Matute-Bello, G
    Winn, RK
    Jonas, M
    Chi, EY
    Martin, TR
    Liles, WC
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A697 - A697
  • [22] T cell apoptosis in human immunodeficiency virus type 1 infection:: Is there a relationship between CD95 sensitivity and thymic regeneration of CD4+ T cells?: Reply
    Hance, AJ
    JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (09): : 1226 - 1227
  • [23] Sensitivity and resistance to apoptosis in the APO-1 (Fas/CD95) system
    Debatin, KM
    ONKOLOGIE, 1996, 19 : 3 - 5
  • [24] Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis
    Schmidt, M
    Lügering, N
    Lügering, A
    Pauels, HG
    Schulze-Osthoff, K
    Domschke, W
    Kucharzik, T
    JOURNAL OF IMMUNOLOGY, 2001, 166 (02): : 1344 - 1351
  • [25] Myofibroblasts (rMF) and hepatic stellate cells (HSC) differ in occurrence of spontaneous apoptosis and CD95 mediated apoptosis inducibility due to differences in the expression of CD95 and CD95L.
    Saile, B
    Matthes, N
    Knittel, T
    Ramadori, G
    HEPATOLOGY, 1998, 28 (04) : 323A - 323A
  • [26] CD95 ligand-induced apoptosis of human medulloblastoma cells
    Weller, M
    Schuster, M
    Pietsch, T
    Schabet, M
    CANCER LETTERS, 1998, 128 (02) : 121 - 126
  • [27] CD95 expression and apoptosis of chronic lymphocytic leukemia B cells
    Cantwell, MJ
    Kipps, TJ
    BLOOD, 1995, 86 (10) : 1370 - 1370
  • [28] Apoptosis of Langerhans cells is controlled by CD95 and BCL-2.
    vonStebut, E
    Hanseleit, U
    Kolde, G
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) : 453 - 453
  • [29] Evaluation of apoptosis and expression CD95 receptor on lymphocyte in prediabetic stage diabetes mellitus type 1
    Glowacka, E
    Banasik, M
    Tchórzewski, H
    Zawodniak-Szalapska, M
    Lewkowicz, P
    DIABETOLOGIA, 2000, 43 : A108 - A108
  • [30] CD95, apoptosis pathways and cancer therapy
    Debatin, KM
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S307 - S308